| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Cancer: slaying the nine-headed Hydra
|
Adashek, J.J.
|
|
|
34 |
1 |
p. 61-69
|
artikel
|
| 2 |
COP27 Climate Change Conference: urgent action needed for Africa and the world ☆
|
Atwoli, L.
|
|
|
34 |
1 |
p. 7-9
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
34 |
1 |
p. iii
|
artikel
|
| 4 |
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Cervantes, A.
|
|
|
34 |
1 |
p. 10-32
|
artikel
|
| 5 |
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
|
Araujo, D.
|
|
|
34 |
1 |
p. 48-60
|
artikel
|
| 6 |
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
|
Tao, Y.
|
|
|
34 |
1 |
p. 101-110
|
artikel
|
| 7 |
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
|
Seufferlein, T.
|
|
|
34 |
1 |
p. 91-100
|
artikel
|
| 8 |
Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy
|
Hua, Y.J.
|
|
|
34 |
1 |
p. 121-123
|
artikel
|
| 9 |
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study ☆
|
Reichert, Z.R.
|
|
|
34 |
1 |
p. 111-120
|
artikel
|
| 10 |
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline ☆
|
Sessa, C.
|
|
|
34 |
1 |
p. 33-47
|
artikel
|
| 11 |
Rules for the conduct of clinical trials need revision, but ‘good clinical practice’ requires much more
|
Salawu, A.
|
|
|
34 |
1 |
p. 4-6
|
artikel
|
| 12 |
Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study) ☆
|
Serra-Aracil, X.
|
|
|
34 |
1 |
p. 78-90
|
artikel
|
| 13 |
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials
|
Perez-Gracia, J.L.
|
|
|
34 |
1 |
p. 70-77
|
artikel
|
| 14 |
Table of Contents
|
|
|
|
34 |
1 |
p. i-ii
|
artikel
|
| 15 |
Thanks to Referees 2022
|
|
|
|
34 |
1 |
p. 1-3
|
artikel
|
| 16 |
VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
|
Mirza, M.R.
|
|
|
34 |
1 |
p. 124-125
|
artikel
|
Tijdschrift beschrijving